The packet definition characterizes pemphigus as autoimmune. It states that some populations may be at greater risk for certain types: people of Jewish descent and those from India, Southeast Europe, and the Middle East for pemphigus vulgaris, and North America, Turkey, and South America for pemphigus foliaceus. No gene is listed in the packet for this condition, and no inheritance pattern is supplied.

No diagnostic methods, diagnostic criteria, or GeneReviews diagnosis section are supplied in this packet, so diagnostic approaches are not described here.

The packet certifies no FDA-approved treatment record and no foundational therapy entries for pemphigus. The packet definition states that treatment includes steroids to reduce inflammation, drugs that suppress the immune system response, and antibiotics to treat associated infections. Orphan drug entries in the packet are designations or withdrawn designations rather than approvals: afamelanotide (Wanbangde Pharmaceutical Group) carries a DESIGNATED status for treatment of pemphigus, while orilanolimab (Alexion Pharmaceuticals) and veltuzumab (Immunomedics) carry a WITHDRAWN status.

Prognosis is not certified in this packet. The packet definition describes pemphigus as a chronic disease and states that early diagnosis and treatment are associated with disease control, without further outcome figures.

The packet certifies 18 active clinical trial records, and active clinical trials for this condition are listed on ClinicalTrials.gov. Examples from the packet: NCT06696716, ONO-4059 in patients with steroid-resistant pemphigus, Phase 3, Ono Pharmaceutical, ACTIVE_NOT_RECRUITING, 2022-08-15 to 2029-03-31; NCT04422912, autologous CAR T cells (RESET-PV) in active pemphigus vulgaris, Phase 1, Cabaletta Bio, RECRUITING, 2020-09-29 to 2029-01-01; and NCT05898308, personalized maintenance therapy compared with standard treatment in pemphigus, Phase 4, University Hospital, Rouen, RECRUITING, 2024-12-04 to 2032-05-01. The packet's publication digest classifies 616 publications, with Case Report / Case Series as the dominant type.